If you want to make a statement of intent, dropping R&D in an entire therapeutic area for which your company is renowned is guaranteed to work, even when the writing had been on the wall for some time.
Sanofi's decision in 2019 to exit diabetes research was the starkest manifestation of the major changes its new CEO...



